Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;26(8):904-914.
doi: 10.1007/s11912-024-01557-y. Epub 2024 Jun 1.

Radiation and Melanoma: Where Are We Now?

Affiliations
Review

Radiation and Melanoma: Where Are We Now?

Roy Bliley et al. Curr Oncol Rep. 2024 Aug.

Abstract

Purpose of review: This review summarizes the current role of radiotherapy for the treatment of cutaneous melanoma in the definitive, adjuvant, and palliative settings, and combinations with immunotherapy and targeted therapies.

Recent findings: Definitive radiotherapy may be considered for lentigo maligna if surgery would be disfiguring. High risk, resected melanoma may be treated with adjuvant radiotherapy, but the role is poorly defined since the advent of effective systemic therapies. For patients with metastatic disease, immunotherapy and targeted therapies can be delivered safely in tandem with radiotherapy to improve outcomes. Radiotherapy and modern systemic therapies act in concert to improve outcomes, especially in the metastatic setting. Further prospective data is needed to guide the use of definitive radiotherapy for lentigo maligna and adjuvant radiotherapy for high-risk melanoma in the immunotherapy era. Current evidence does not support an abscopal response or at least identify the conditions necessary to reliably produce one with combinations of radiation and immunotherapy.

Keywords: Immunotherapy; Melanoma; Radiotherapy; Stereotactic body radiotherapy; Stereotactic radiosurgery; Targeted therapy.

PubMed Disclaimer

Similar articles

Cited by

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. - PubMed - DOI
    1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40(2):127–37. A phase 3 study showing a 57% melanoma-specific survival rate at 5 years with D-ICI for stage III-IV melanoma patients, much improved from historical outcomes.
    1. Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys. 1991;20(3):429–32. - PubMed - DOI
    1. Scott GA. Differential diagnosis in dermatopathology III. Arch Dermatol. 1993;129(6):804. - DOI
    1. McKenna JK, Florell SR, Goldman GD, Bowen GM. Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment. Dermatol Surg. 2006;32(4):493–504. - PubMed

MeSH terms

LinkOut - more resources